Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,808

Researchers at the University of Pittsburgh in collaboration with Magee Women’s Research Institute are developing a nasal spray that they say can possibly prevent a coronavirus infection.

The active ingredient used in the nasal spray is a protein called Q-Griffithsin, which is extracted from algae and tobacco plants. The researchers believe that this protein molecule will bind to the coronavirus and prevent it from infecting healthy cells.

The protein molecule was originally developed to potentially prevent several other infections. Animal studies revealed that Q-Griffithsin worked effectively against MERS, SARS, hepatitis, Ebola, and several other viruses.

Read more | >

Dark-matter device will use a Bose–Einstein condensate of rubidium-87 atoms to search for axions. Plus, the science still isn’t clear on how children spread the coronavirus and the month’s best science images. Dark-matter device will use super-cooled atoms to search for axions. Plus, the science still isn’t clear on how children spread the coronavirus and the month’s best science images.

Read more | >

The company said it expects to “incur significant expenses this year” related to the development of and manufacturing of its potential vaccine. However, it added that it expects “a close matching of expenses and reimbursements for those expenses” from its award by the Biomedical Advanced Research and Development Authority.

BARDA, which is a part of the Department of Health and Human Services, last month warded Moderna up to $483 million in funding to accelerate development of the Covid-19 vaccine candidate.

The race to develop anything to fight the coronavirus is intensely competitive and investors are watching closely for signs of progress on treatments and vaccines. Moderna, as well as other companies in the race, is ramping up manufacturing ahead of approval so that it can rapidly distribute doses if their candidate proves effective against the virus and safe for humans.

Read more | >

For the first time, researchers have succeeded in creating strong coupling between quantum systems over a great distance. They accomplished this with a novel method in which a laser loop connects the systems, enabling nearly lossless exchange of information and strong interaction between them. In the journal Science, physicists from the University of Basel and University of Hanover reported that the new method opens up new possibilities in quantum networks and quantum sensor technology.

Quantum technology is currently one of the most active fields of research worldwide. It takes advantage of the special properties of quantum mechanical states of atoms, light, or nanostructures to develop, for example, novel sensors for medicine and navigation, networks for information processing and powerful simulators for materials sciences. Generating these quantum states normally requires a between the systems involved, such as between several atoms or nanostructures.

Until now, however, sufficiently strong interactions were limited to short distances. Typically, two systems had to be placed close to each other on the same chip at low temperatures or in the same vacuum chamber, where they interact via electrostatic or magnetostatic forces. Coupling them across larger distances, however, is required for many applications such as or certain types of sensors.

Read more | >

As the number of confirmed COVID −19 cases worldwide approaches 4 million and the pandemic could be with us for months or years, we look at who can access drugs like remdesivir, being developed by pharmaceutical giant Gilead, which has the patent for the drug and is poised to make massive profits. We look at how much drugs like remdesivir will cost, and who can access them, with writer Achal Prabhala, coordinator of the AccessIBSA project, which campaigns for access to medicines in India, Brazil and South Africa.

This is viewer supported news. Please do your part today.

Read more | >

The new coronavirus invades the body through a spike protein that lives on the surface of virus cells. The S protein, as it’s called, binds to a receptor called angiotensin-converting enzyme 2 (ACE2) on a healthy cell’s surface. Once attached, the cells fuse and the virus is able to infect the healthy cell.

ACE2 receptors are present on cells in many places throughout the body, and especially in the lungs. Cells in the lungs are also some of the first to encounter the virus, since the primary form of transmission is thought to be breathing in droplets after an infected person has coughed or sneezed.

That’s why it was necessary to upgrade Stem Cell Neurotherapy for COVID-19 by adding T-Cells, B-Cells, and Natural Killer Cells to the arsenal. It was not enough to just regenerate new lung cells to replace the lung cells infected by COVID-19, but the COVID-19 Virus Cells had to be attacked and destroyed in order to prevent them from invading and infecting the newly regenerated lung cells.

So, that’s where the idea of using T-Cells, B-Cells, and Natural Killer Cells, usually used in attacking cancer cells, came from.

Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn’t get too carried away just yet.

Read more | >

Few cases and no deaths. I would listen to those who have success, not those who have failure. Scientists from failing countries have warned not to take just about everything to fight this. The WHO’s abysimal performance shows they are the last people anyone should listen to. Show the efficacy of WHO advice, or even ventilators for that matter vs Continuous Positive Airway Pressure (CPAP). If people want to use something to fight this let them, you have the choice of not using it.

Madagascar’s President Andry Rajoelina tries Covid-Organics at a launch ceremony in Antananarivo on 20 April. Several other African leaders have expressed an interest in the unproven treatment.

Read more | >

Diagnosing COVID-19 more quickly, easily, and broadly

With COVID-19 rapidly spreading around the planet, the efficient detection of the CoV2 virus is pivotal to isolate infected individuals as early as possible, support them in whatever way possible, and thus prevent the further uncontrolled spread of the disease. Currently, the most-performed tests are detecting snippets of the virus’ genetic material, its RNA, by amplifying them with a technique known as “polymerase chain reaction” (PCR) from nasopharyngeal swabs taken from individuals’ noses and throats.

The tests, however, have severe limitations that stand in the way of effectively deciding whether people in the wider communities are infected or not. Although PCR-based tests can detect the virus’s RNA early on in the disease, test kits are only available for a fraction of people that need to be tested, and they require trained health care workers, specialized laboratory equipment, and significant time to be performed. In addition, health care workers that are carrying out testing are especially prone to being infected by CoV2. To shorten patient-specific and community-wide response times, Wyss Institute researchers are taking different parallel approaches:

Read more | >